Search Results
Your search for ,itS matches 8761 pages
Showing 3451 - 3500IASLC Appoints Chandra P. Belani, MD, as New Chief Science Officer
The International Association for the Study of Lung Cancer (IASLC) has named Chandra P. Belani, MD, as its new Chief Science Officer. In this position, Dr. Belani will direct, guide, and support the IASLC scientific strategy, including, but not limited to, scientific research projects,...
First Department of Veterans Affairs System Achieves QOPI® Certification
The Quality Oncology Practice Initiative (QOPI®) Certification Program continues to expand its reach, certifying the first system within the U.S. Department of Veterans Affairs (VA)—the Salisbury VA Health Care System—on October 9. The system, which includes a main facility—the W. G. (Bill) Hefner...
Conquer Cancer®, the ASCO Foundation, Hosts Scientific and Career Development Retreat
Conquer Cancer®, the ASCO Foundation, hosted its fifth annual Scientific and Career Development Retreat on October 29 and 30, 2019, at ASCO Headquarters in Alexandria, Virginia. The event encourages networking and scientific collaboration among Young Investigator Award (YIA) and Career Development...
JOP Editor-in-Chief Brings Value-Based Care to Journal’s Forefront
In January 2019, Linda D. Bosserman, MD, FACP, FASCO, began her tenure as Editor-in-Chief of the Journal of Oncology Practice (JOP). An Assistant Clinical Professor and staff physician at City of Hope, Dr. Bosserman has served on the ASCO Board of Directors and was a founding member of the TAPUR...
I Do Not Have a Multiple Myeloma Precursor Condition. Why Not?
For the country, and for me personally, 2001 was a watershed year. In May, my mother died; the following month my brother, Dom, then 57, called to tell me he had just been diagnosed with multiple myeloma. Except for some fatigue Dom had complained about at our mother’s funeral, there were no...
Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Combination therapy with the programmed cell death ligand 1 inhibitor atezolizumab and the vascular endothelial growth factor inhibitor bevacizumab significantly improved overall and progression-free survival in patients with unresectable hepatocellular carcinoma compared with sorafenib, according...
Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study. Binghe Xu, MD, PhD, of the Department of ...
Making Inroads With Interventional Oncology in the Treatment of Solid Tumors
At the recent 2019 Symposium on Clinical Interventional Oncology (CIO) in Miami, course directors Constantino Peña, MD, FSIR, and Ripal Gandhi, MD, FSIR, FSVM, had a lot to say about this burgeoning field of oncology. In particular, interventional oncology is making inroads in therapeutic...
ASH Recognized Choosing Wisely Champions at 2019 Annual Meeting & Exposition
The American Society of Hematology (ASH) recognized three Choosing Wisely® Champions, practitioners working to tackle the overuse of hematology tests and treatments, at its 2019 Annual Meeting & Exposition in Orlando: Stephen L. Wang, MD, of Kaiser Permanente Santa Clara Medical Center, Santa...
ClarIDHy and FIGHT-202 Trials Show Positive Results in the Treatment of Patients With Biliary Tract Cancer
Two studies reported at the European Society for Medical Oncology (ESMO) Congress 2019—ClarIDHy and FIGHT-202—demonstrated clinical benefits with novel molecularly targeted agents in the treatment of advanced cholangiocarcinoma. Currently, first-line treatment for locally advanced or metastatic...
Addition of Daratumumab Increases Benefit of Carfilzomib/Dexamethasone in Multiple Myeloma
In patients with relapsed or refractory multiple myeloma, the addition of daratumumab to carfilzomib plus dexamethasone improved multiple outcomes, compared with carfilzomib/dexamethasone alone, in the international phase III CANDOR trial.1 “Overall, carfilzomib/dexamethasone/daratumumab was...
ASH 2019: Dose-Climbing Trial of Dual-Target CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma
More than three out of four patients with relapsed multiple myeloma, or myeloma that was refractory to at least two therapies, remained in remission 7 months after treatment with a novel chimeric antigen receptor (CAR) T-cell therapy targeting two proteins that are frequently found on myeloma...
ASH 2019: Phase Ib/II Study of BCMA-Directed CAR T-Cell Therapy for Pretreated Multiple Myeloma
Patients with multiple myeloma who had received a median of five prior therapies with refractory disease had a high response rate when treated with the investigational chimeric antigen receptor (CAR) T-cell therapy JNJ-4528, which targets B-cell maturation antigen (BCMA), a protein commonly found...
Role of Integrative Therapies for Patients With Colorectal Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Richard T. Lee, MD, describes the symptoms associated with colorectal cancer...
‘Unexpected’ Survival Benefit With Trilaciclib Plus Chemotherapy in Triple-Negative Breast Cancer
An unanticipated result of a randomized phase II study was the improvement in overall survival achieved with the investigational CDK4/6 inhibitor trilaciclib in women with metastatic triple-negative breast cancer. The drug was not being evaluated for its anticancer effects, but rather as a means of ...
Checkpoint Inhibitor Pneumonitis: A Pulmonologist’s Perspective
Oncologists have become accustomed to seeing pneumonitis associated with immune checkpoint inhibitor treatment in non–small cell lung cancer (NSCLC), requiring intervention by pulmonologists in the management of severe cases. At CHEST 2019, the annual meeting of the American College of Chest...
Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer
In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...
How the PROMISE Study Aims to Convert Multiple Myeloma Into a Preventable Cancer
In 2018, researchers from Dana-Farber Cancer Institute launched a large, ambitious screening study called (PROMISE; ClinicalTrials.gov identifier NCT03689595) to identify people with premalignant precursor conditions of multiple myeloma, to understand the molecular signs of progression to myeloma...
Geriatric Assessment–Guided Multidisciplinary Care May Benefit Older Patients Undergoing Stem Cell Transplantation
Older adults with blood cancers may benefit from a team-based, holistic evaluation before undergoing transplantation, according to a study published by Derman et al in Blood Advances. The study, which reported on a multidisciplinary clinic at the University of Chicago Medical Center, found that...
FDA Pipeline: Recent Designations in Hepatocellular Carcinoma, Cholangiocarcioma, Lymphoma, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) granted reviews or designations to treatments for gastrointestinal cancers and lymphoma, and also provided authorizations for products designed to screen for malignancies and tumor mutational burden. Priority Review for Nivolumab...
ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported by Xu et al at the European...
ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Combination therapy with the programmed cell death ligand 1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improved overall and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to sorafenib, according to findings from the phase ...
ASCO Statement Says FDA Should Implement Proposed Rule for Graphic Labels on Cigarette Packs and Ads
ASCO submitted comments to the U.S. Food and Drug Administration (FDA) applauding its proposed rule to implement the use of new graphic warning labels on cigarette packaging and advertisements. The comments were sent in a letter from 2019–2020 ASCO President Howard A. Burris III, MD, FACP, FASCO, ...
ASCO President-Elect Candidates Discuss Key Issues in Oncology
Patrick J. Loehrer, MD, FASCO, of the Indiana University Melvin and Bren Simon Cancer Center, and Everett E. Vokes, MD, FASCO, of the University of Chicago Medicine Comprehensive Cancer Center, were selected by the ASCO Nominating Committee as candidates for President-Elect. Below, they discuss...
National Academy of Medicine Elects New Members, Including Many From Oncology Community
The National Academy of Medicine has announced the election of 90 regular members and 10 international members during its Annual Meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding ...
Using the Nobel Prize to Champion Curiosity-Driven Research in Cancer
William G. Kaelin, Jr, MD, Sidney Farber Professor of Medicine and Howard Hughes Medical Institute Investigator at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, admits that early in his research career, he and his late wife, Carolyn, would have fun...
When to Consider Local Therapy for Stage IV Breast Cancer
Local therapy for stage IV breast cancer has not been proven to increase overall survival, yet there are some cases where local therapy could be considered outside a clinical trial. For patients with intact asymptomatic primary tumors, local therapy could be offered if distant disease is well...
A Diagnosis of Multiple Myeloma Taught Me to Live in the Moment
I was just 39 in 2015 when I was diagnosed with multiple myeloma. I have a wife and three young children whom I love, a challenging and fulfilling career, and I wasn’t ready to die. When I was first diagnosed, I met with a medical oncologist who had little experience treating this type of cancer....
MD Anderson and University of Puerto Rico Receive $13 Million Grant Renewal
The University of Texas MD Anderson Cancer Center and the University of Puerto Rico received a competitive renewal of their Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) grant from the National Cancer Institute. The CPACHE grant provides a total of $13 million over 5 years....
Wake Forest Baptist Awarded $6 Million Grant to Study Web-Based Pain Management Program
For many people who have had cancer, severe pain can persist, even after treatment ends. In an effort to find a nonpharmaceutical approach to pain management for cancer survivors, researchers at Wake Forest Baptist Health have been awarded $6 million from the National Cancer Institute (NCI) to test ...
Early Palliative Care for Patients With Hematologic Malignancies: Beneficial but Underused
The use of billed palliative care services among Medicare beneficiaries with hematologic malignancies has risen dramatically in recent years, but most encounters still occur within days of death, according to research presented at the 2019 Supportive Care in Oncology Symposium.1 The analysis of...
Despite Challenges, Pioneer in CT Screening for Early Lung Cancer Works to Move the Field Forward
In 1999, a team of researchers from Weill Cornell Medical College advocated the use of a then-novel practice: low-dose radiation CT screening for lung cancer. It captures a full thoracic image in a single breath hold, and can recognize a tumor in its earliest stages when the chance for cure is...
Trifluridine/Tipiracil in Recurrent, Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Early in 2019, trifluridine/tipiracil tablets were approved for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine; a platinum; either a taxane or...
Expert Point of View: Charles L. Loprinzi, MD
Charles L. Loprinzi, MD, Regis Professor of Breast Cancer Oncology at the Mayo Clinic, in Rochester, Minnesota, discussed the abstract on oncology massage to treat chemotherapy-induced peripheral neuropathy. He said that although massage therapy shows promise for this patient population, its...
Novel Therapies for Small Cell Lung Cancer and Neuroendocrine Tumors
Here is a glimpse at updated clinical trial data on newer therapies under study for the small cell lung cancer (SCLC) and advanced extrapancreatic neuroendocrine tumors. IMpower133 and ALTER: Novel Therapies for SCLC The treatment of small cell lung cancer has seen little progress in recent years,...
Stanford Medicine Division of Oncology Welcomes Three New Faculty Members
The Stanford Medicine Department of Medicine is excited to welcome three faculty members to its Division of Oncology: Curtis Chong, MD, PhD; Fauzia Riaz, MD; and Shagufta Shaheen, MD. Each of these individuals brings an impressive record of academic pursuits focused on advancing care for and...
A Need for Human Connection Led to a Rewarding Career in Geriatric Oncology for Lodovico Balducci, MD
Older adults are the fastest-growing segment of our population, and more than 65% of patients with newly diagnosed cancer are 65 years of age or older. Although we now recognize the special needs of older patients with cancer, the field of geriatric oncology emerged quietly, with early growing...
An Oncologist’s Thoughtful Examination of Cancer and Personal Loss
“I could not have written this book when I was 30 years old. It is not because of any great discoveries I have made or research papers I have published since. It is because of the experience the intervening decades have given me as I cared for thousands of cancer patients and accompanied many to...
Navneet S. Majhail, MD, MS, Was Inspired by His Father’s Career as a Military Doctor and His Mother’s Battle With Cancer
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Navneet S. Majhail, MD, MS, about his journey from India to the Cleveland Clinic, where he is Director of the Blood and Marrow Transplant Program. He is also President of the American Society for...
Addressing the Obesity Epidemic and Barriers to Implementing Weight Management Programs for Cancer Survivors
Earlier this year, ASCO published the results of its new study on oncologists’ perceptions and practice behaviors regarding obesity, weight management, and related lifestyle factors in their patients both during and after cancer treatment.1 The findings from the online survey of 971 oncology...
Expert Point of View: Ian Chau, MD
The invited discussant for the ATTRACTION-3 study was Ian Chau, MD, Consultant Medical Oncologist at The Royal Marsden Hospital, London and Surrey, United Kingdom. Dr. Chau first congratulated the investigators for successfully conducting a randomized phase III trial in metastatic esophageal...
With a Little Help From My Friends: Social Support Linked to Pain Reduction in Patients With Cancer
Pain may be one of the most common symptoms experienced by patients with cancer, but researchers are still unpacking its mysteries, with some surprising results. According to data presented at the 2019 Supportive Care in Oncology Symposium,1 greater social support may help mitigate pain in patients ...
ASCO Provides Guidance on Managing Osteoporosis in Cancer Survivors
Cancer survivors are at an increased risk of osteoporotic fractures due to the accelerated loss of bone mineral density as a result of their treatment. Bone loss from cancer therapy is faster and more severe than bone less from aging; rates of bone loss are up to sevenfold higher when they occur...
Affirming Universal Health Care as a Fundamental Human Right
This year’s meeting of the World Cancer Leaders’ Summit: Cancer and Universal Health Coverage, held on October 15–17 in Nur-Sultan, Kazakhstan, brought together more than 350 global health leaders, including ministers of health, first ladies, and industry leaders, from 82 countries to discuss how...
FDA Office of Hematology Oncology Products Reorganized, Renamed Office of Oncologic Diseases
As part of modernization plans approved in September 2019, the U.S. Food and Drug Administration (FDA) office responsible for reviewing applications for new and existing cancer therapies has reorganized and been renamed. The Center for Drug Evaluation and Research (CDER) Office of Hematology and...
Expert Point of View: Arndt Vogel, MD and Angela Lamarca, MD, PhD
Arndt Vogel, MD, of Hannover Medical School in Germany, who served as discussant of the two studies of immunotherapy in hepatocellular carcinoma, said the findings point to a promising future in the treatment of this malignancy. He commented that the responses observed with nivolumab in CheckMate...
American Society of Hematology Honors Posthumously Stanley L. Schrier, MD, With 2019 Exemplary Service Award
The American Society of Hematology (ASH) recognized Stanley L. Schrier, MD, a Past ASH President and formerly Professor Emeritus of Medicine in Hematology at Stanford School of Medicine, California, with the 2019 Exemplary Service Award for his years of service and dedication to ASH and to...
Maximizing Benefit in the Treatment of Immune-Mediated Colitis
Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...
American Society for Dermatologic Surgery Awards Eight Research Grants
The American Society for Dermatologic Surgery (ASDS) has announced eight grant recipients across three research programs to support its mission to foster, develop, and encourage investigative knowledge in dermatologic surgery. Jumpstart Research Seed Grants Three Jumpstart Research Seed Grants were ...
City of Hope’s Michael Caligiuri, MD, Formally Appointed to Deana and Stave Campbell Physician-in-Chief Distinguished Chair
Michael A. Caligiuri, MD, President of City of Hope National Medical Center, in Duarte, California, has been appointed the Deana and Steve Campbell Physician-in-Chief Distinguished Chair in Honor of Alexandra Levine, MD. The position was created in honor of Dr. Levine, a City of Hope Professor of...
